| 000 | 01688 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516121217.0 | ||
| 264 | 0 | _c20130701 | |
| 008 | 201307s 0 0 eng d | ||
| 022 | _a1472-6963 | ||
| 024 | 7 |
_a10.1186/1472-6963-12-385 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWu, Bin | |
| 245 | 0 | 0 |
_aCost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. _h[electronic resource] |
| 260 |
_bBMC health services research _cNov 2012 |
||
| 300 |
_a385 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aChina |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xeconomics |
| 650 | 0 | 4 |
_aEmergency Treatment _xeconomics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLamivudine _xeconomics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 |
_aOrganophosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aPatient Simulation |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aShen, Jinfang | |
| 700 | 1 | _aCheng, Huafeng | |
| 773 | 0 |
_tBMC health services research _gvol. 12 _gp. 385 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1472-6963-12-385 _zAvailable from publisher's website |
| 999 |
_c22249715 _d22249715 |
||